Zachary Bessette

DocwireNews

The United States Food and Drug Administration (FDA) has <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection" target="_blank" rel="noopener">granted approval</a> for atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection in adult patients with hepatocellular carcinoma (HCC).
The atezolizumab and hyaluronidase-tqjs subcutaneous combination was also approved for non-small cell lung cancer, small cell lung cancer, melanoma, and alveolar soft part sarcoma.
FDA approval comes after the results of the IMscin001 trial, an open-label, multi-center, international analysis of adult patients who were not previously treated with immunotherapy and who had not experienced disease progression following treatment with platinum-based chemotherapy. In the trial, a total of 371 patients were randomized (2:1) to receive subcutaneous atezolizumab and hyaluronidase-tqjs or intravenous atezolizumab until disease progression or unacceptable toxicity.
The primary outcome measure of IMscin001 was atezolizumab exposure. The co-primary pharmacokinetic endpoints were Cycle 1 Ctrough and AUC0-21days. Additional efficacy outcome measures included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
The geometric mean ratio (90% CI) of subcutaneous atezolizumab and intravenous atezolizumab for Cycle 1 Ctrough was 1.05 and 0.87 for AUC0-21days. These met the lower limit of the geometric mean ratio (90% CI) above the pre-specified threshold of 0.80 for comparability.
No notable differences were reported between the different formulations with regard to ORR, PFS, or OS; the confirmed ORR was 9% in the subcutaneous atezolizumab and hyaluronidase-tqjs arm and 8% in the intravenous atezolizumab arm.
Common adverse events of any grade included fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.
The FDA noted that the recommended dosage is a single subcutaneous injection (15 mL containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) administered in the thigh over a 7-minute span every 3 weeks.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

FDA Approves Atezolizumab, Hyaluronidase-tqjs Subcutaneous Injection for HCC

Liver Cancer

FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.

FDA Approves Atezolizumab, Hyaluronidase-tqjs Injection for HCC

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe